Astellas, the original company of the oral androgen receptor inhibitor (ARTA) class prostate cancer treatment, became the first company to receive marketing authorization for the tablet formulation of Xtandi in Korea.

The Ministry of Food and Drug Safety approved two dosage forms of Astellas' Xtandi Tab - 40 mg and 80 mg – on March 3.

Since Astellas received approval for ‘Xtandi Soft Capsules 40 mg (enzalutamide)’ in Korea in 2013, the company has only been supplying the soft capsule formulation until now.

Soft capsule formulations have a disadvantage in that increasing the dose increases the size of the capsule itself, which can reduce patient convenien